Abstract: Disclosed is a 5-acylamino-2-arylazo, nitro, or nitroso-4-substituted-phenol having the structural formula I: wherein: R* is an arylazo, nitro, or nitroso group, Y is a coupling-off group, and R′ is a substituent group. Also disclosed is a method of using the compound in a simplified process for making a photographic coupler.

Abstract: Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula or the pharmaceutically acceptable salts thereof wherein Ar, R1, R2, A, and Z are various organic and inorganic substituents.

Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N-phenyl-N-heteroaralkyl aminoalcohols.

Abstract: A compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof; wherein; R1 and R2, which may be the same or different, are hydrogen, C1-C6alkyl, (CH2)m (C3-C6cycloalkyl) wherein m =0, 1, 2 or 3, or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; each R3 is independently CF3, OCF3, C1-4alkylthio or C1-C4alkoxy; n is 1, 2 or 3; and R4 and R5, which may be the same or different, are: A—X, wherein A =—CH=CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; R6, R7, R8 and R10 which may be the same or different, are hydrogen or C1-6alkyl optionally substituted independently by one or more R12; R9 is C1-6 alkyl optionally substituted independently by one or more R12; R11 is hydrogen, C1-6 alkyl optionally substituted independently by one or more R12, C(O

Abstract: Compounds characterized generally as imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino dial derivatives are useful as renin inhibitors for the treatment of hypertension.

Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to prodrugs of compounds which selectively inhibit cyclooxygenase-2. The use of non-steroidal antiinflammatory drugs (NSAIDs) in treating pain and the swelling associated with inflammation also produce severe side effects, including life threatening ulcers. The recent discovery of an inducible enzyme associated with inflammation (“prostaglandin G/H synthase II” or “cyclooxygenase-2 (COX-2)”) provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.

Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.

Abstract: The invention relates to benzamidoxim derivatives of formula (I) wherein the substituents have the following meanings: R1 represents difluoromethyl or trifluoromethyl, R2 represents hydrogen or fluorine, R3 represents C1-C4 alkyl optionally substituted with cyano, C1-C4 halogenalkyl, C1-C4 alkoxy-C1-C4 alkyl, C3-C6 alkenyl, C3-C6 halogenalkenyl, C3-C6 alkinyl, C3-C8 cycloalkyl-C1-C4 alkyl, R4 represents phenyl-C1-C6 alkyl, which can carry one or more substituents selected from the group composed of halogen, C1-C4 alkyl, C1-C4 halogenalkyl, C1-C4 alkoxy or C1-C4 halogenalkoxy on the phenyl ring, or thienyl-C1-C4 alkyl, which can carry one or more substituents selected from the group composed of halogen, C1-C4 alkyl, C1-C4 halogenalkyl, C1-C4 halogenalkoxy on the thienyl ring, or pyrazol-C1-C4 alkyl, which can carry one or more substituents selected from the group composed of halogen, C1-C4 alkyl, C1-C4 halogenalkyl, C1-C4 alkoxy or C1-C4 halogenalkoxy on the pyrazol ring.

Abstract: Compounds represented by the general formula (1): [wherein R1 is typically an aminoalkyl group; R2 is typically a hydrogen atom, a lower alkyl group, R3 or SR4 (where R4 is typically a lower alkyl group); Ar is typically a 5-membered aromatic heterocyclic group] have an NOS inhibiting activity and are useful as therapeutics of cerebrovascular diseases and other pharmaceuticals.

Abstract: 1-Guanylpyrazole acid adducts of the formula: wherein R1, R2 and R3 independently of one another are hydrogen, a branched or straight-chain C1-6-alkyl group, a C3-8-cycloalkyl group or a C6-12-aryl group which is unsubstituted or substituted by 1 to 6 alkyl groups; R4 is hydrogen or a straight-chain or branched C1-4-alkyl group; and X is Cl or Br, are prepared by a process which comprises: conducting the reaction of pyrazole or a derivative thereof with cyanamide or a derivative thereof and gaseous hydrogen chloride or hydrogen bromide in an aprotic solvent.

Abstract: The thienylazolylalkoxyethanamines (I) where R1 is a hydrogen atom, a halogen atom or a lower alkyl radical; R2, R3 and R4 represent, independently, a hydrogen atom or a lower alkyl radical; and Az represents a five-member nitrogenated hetercyclic aromatic group, N-methyl-substituted, that contains from one to three nitrogen atoms. They have analgesic activity in mammals, including humans. The compounds (I) can be obtained, for example, by reaction of a derivative of hydroxy-thienylazol (IV) with a derivative of a suitable N-(ethyl)amine. The compounds (IV) are useful intermediates in the synthesis of the compounds (I). The compounds (I) have an application in human and/or veterinary medicine.

Abstract: The present application describes aryl sulfonyls of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein D, E, and M are defined below, are effective factor Xa inhibitors.

Abstract: A process for making a compound of formula I wherein the substituents are as described in the specification comprising reacting a ketone of formula II with succinic anhydride and an alkoxide base to form a compound of formula III which is reacted with a compound of formula IV to form a compound of V and reacting with an alcohol to form the corresponding ester of formula VI and reacting the ester with N-methylhydroxylamine.

Abstract: Compositions including at least one organic ligand including a first hetero atom and a second hetero atom directly bonded to the first hetero atom or located one carbon atom away from the first hetero atom, with at least one of the hetero atoms being nitrogen, and a transition metal moiety partially complexes by the organic ligand are provided. Such complexes have a controlled adaptable proton transfer ability and/or a hydrogen bonding ability which makes such compositions particularly useful as chemical reaction facilitators. Examples of chemical reactions facilitated by such compositions include hydrolysis reactions and carbon dioxide conversion reactions.

Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Abstract: 1-Guanylpyrazole acid adducts of the formula: 1

Abstract: N-Phenylpyrazole derivatives of the formula: wherein R1 represents optionally halogenated alkyl; R2 represents halogen, cyano, nitro, cycloalkyl, alkenyl, thiocyanato, optionally alkyl substituted sulphamoyl, optionally alkyl substituted carbamoyl, alkoxycarbonyl, alkanoyl or optionally halogenated alkyl; and R3 represents a hydrogen atom or a group N″R′″ or a variety of other groupings. These compounds possess arthropodicidal, plant nematocidal, anthelmintic and anti-protozoal properties; their preparation, compositions containing them and their use are described.

Abstract: A process for making a compound of formula I wherein the substituents are as described in the specification comprising reacting a ketone of formula II with succinic anhydride and an alkoxide base to form a compound of formula III 1

Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.

Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for stimulating the growth of neurites in nerve cells. The compounds and the compositions and methods that utilize them can be used, either alone or in conjunction with a neurotrophic factor, such as nerve growth factor, to promote repair of neuronal damage caused by disease or physical trauma.

Abstract: The invention relates to novel compositions for the oxidation dyeing of keratin fibers, comprising at least one specific diaminopyrazole derivative, to the dyeing process using this composition, to novel diaminopyrazole derivatives and to a process for their preparation.

Abstract: Compounds of the formula I in which R1 is C1-C4alkyl; R2 is cyano or NH2C(S)—; R3 is hydrogen, C1-C4alkyl, C1-C4haloalkyl, C3- or C4alkenyl, C3- or C4alkynyl, C3-C8haloalkenyl, NC—CH2—, HOC(O)—CH2— or C1-C4alkoxy-C(O)—CH2—; W is a group  and R4 to R6, R60, R61, R70, X1, X2, n1 and A1—B1 are as defined in claim 1, and the pyrazole N-oxide, agronomically acceptable salts and stereomers of these compounds of the formula I, with the exclusion of the compound of the formula  have good selective herbicidal properties when used pre- and post-emergence. The preparation of these compounds and their use as herbicidally active ingredients are described.

Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.

Abstract: The present invention relates, among many things, to novel 4,5-dihydro-1H-pyrazole compounds which can be potent antagonists of the cannabis CB1-receptor.

Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; or R1 and R2 taken together may form a bivalent radical of formula —(CH2)n— wherein n is 2, 3, 4, 5 or 6; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or —NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alk

Abstract: Fluorocarbon compounds are synthesized by reacting a substrate hydrocarbyl compound containing at least one sp3-hybridized halophoric carbon atom bearing at least two halogen atom substituents, at least one of which is a halogen atom having an atomic number greater than that of fluorine and the at least one halophoric carbon atom being bonded to at least one chalcogen, with at least one reactant which comprises a complex of a Bronstedt base with a defined amount n of hydrofluoric acid, n being at least 3 and not greater than 20.

Abstract: A compound of the formula (I): wherein: R1 is chlorine, difluoromethyl, trifluoromethyl or cyano; and R2is a group having the formula:  wherein: X is halogen, cyano, nitro or amino; Y1 is lower alkyl or lower alkoxy; and Z is halogen; or a pharmaceutically acceptable salt thereof.

Abstract: Novel aromatic heterocyclic compounds inhibit cytokines production involved in immunoregulation and inflammation such as interleukin-1 and tumor necrosis factor production. The compounds are therefore useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases.

Abstract: Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula or the pharmaceutically acceptable salts thereof wherein Ar, R1, R2, A, and Z are various organic and inorganic substituents.

Abstract: The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

Abstract: The present invention provides compounds of formula I and processes for the preparation and purification thereof. Compounds of formula I are useful as intermediates in the manufacture of 6-(arylcarbonyl)-4-oximino-dihydrobenzothiopyran herbicidal agents.

Abstract: The present invention provides compounds of formula I and processes for the preparation and purification thereof.

Abstract: Compounds of formula (I) or pharmaceutically, veterinarily or agriculturally acceptable salts thereof, or pharmaceutically, veterinarily or agriculturally acceptable solvates of either entity, wherein R1 is 2,4,6-trisubsituted phenyl or 3,5-disubstituted pyridin-2-yl; R3 is C1-C4 alkyl optionally substituted with hydroxy or with one or more halo; cyano, C1 to C5 alkanoyl or phenyl R5 is hydrogen, C1 to C4 alkyl, amino or halo; R2 and R4 are each independently selected from hydrogen, C1 to C4 alkyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a C3 to C6 cycloalkyl group; R6 and R8 are each independently selected from hydrogen, C1 to C4 alkyl, fluoro, chloro and bromo; or; when R2 and R4 do not form part of a cycloalkyl group, R2 and R6, together with the carbon atoms to which they are attached, may form a C5 to C7 cycloalkyl group; and R7 is hydrogen, C1 to C4 alkyl optionally substituted with one or more halo; or C1 to C4 alkoxy; are parasitici

Abstract: Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.

Abstract: The invention relates to new diphenyl-substituted 5-ring heterocycles of general formula (I) wherein A, X and the groups R1, R2, R3, R4 and R5 are defined as in the claims, processes for preparing them and their use as pharmaceutical compositions.

Abstract: Parasiticidal pyrazole derivatives of formula (I) wherein: R1 represents CN, C1-6 alkoxycarbonyl, NO2, CHO, C1-6 alkanoyl, phenyl optionally substituted by one or more halogen, or C1-6 alkyl optionally substituted by one or more halogen; R2 represents a group of formula (II), (III) or (IV) in which: R7 represents H, halogen, carbamoyl, cyano, tri(C1-6 alkyl)silyl, C1-6 alkyl (optionally substituted by one or more halogen, OH or C1-6 alkoxy), C1-6 alkoxycarbonyl, phenyl, or a 5- or 6-membered ring heterocycle which is saturated or partially or fully unsaturated and contains up to 4 hetero-atoms independently selected from up to 4 N atoms, up to 2 O atoms and up to 2 S atoms and which is attached to the alkynyl moiety by an available C, S or N atom where the valence allows; and R8, R9 and R10 each independently represents H, halogen, phenyl optionally substituted by one or more halogen, CN or C1-6 alkyl optionally substituted by one or more halogen; R3 represents H, C1-6 alkyl, halogen, NH2, NH(C1-6 alkanoyl),

Abstract: This invention relates to herbicidal alpha-(2,4,5-trisubstituted)- and alpha-(2,5-disubstituted)-benzoyloxy-alpha-beta-, and/or beta-gamma-unsaturated-carboxylates and their derivatives, to compositions which contain these compounds, and to methods of use of these compounds.

Abstract: The procedure comprises reacting the mixture that comprises 2-[phenyl(1-methyl-1 H-pyrazole-5-yl)methoxy]-N,N-dimethylethanamine (I) with an enantiomer of an optically active acid to form a diastereoisomeric salt, separating said salt and liberating the enantiomer of said compound (I). The dextrorotatory enantiomer of (I) can be obtained by reacting a racemic mixture or non-racemic mixture of (I) with (+)-ditoluyl-L-tartaric acid, optionally mixed with p-toluensulphonic acid. Compound (I) has analgesic properties and its most active enantiomer is dextrorotatory.

Abstract: Acrylonitrile compounds having pesticidal activity of formula (I) and salts thereof. wherein Q is Y is ═C(R4)— or ═N—, R1 is alkyl, haloalkyl, etc., each of R2 and R3 is halogen, alkyl which may be substituted, alkenyl which may be substituted, etc., R4 is hydrogen, halogen, alkyl or haloalkyl, 1 is from 1 to 4, m is from 0 to 5, n is from 0 to 3, q is from 0 to 4, when 1 is 2 or more, a plurality of R2 may be the same or different, when each of m, n and q is 2 or more, a plurality of R3 may be the same or different.